US EditionPublished • loading... • Updated
US COYA 302 trial in ALS expands to Canada after regulatory nod
Summary by ALS News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
US COYA 302 trial in ALS expands to Canada after regulatory nod
Health Canada has cleared the way for people with amyotrophic lateral sclerosis (ALS) living in Canada to join an ongoing clinical trial evaluating Coya Therapeutics’ therapy candidate COYA 302. The Canadian regulatory agency issued a “no objection” letter that will allow the developer to start enrolling adults in its Phase 2 ALSTARS study (NCT07161999), slated to run through 2027. Coya plans to recruit approximately 120 participants, ages 18 to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
